Intermittent Sargramostim Administration Expands Proliferating Naive T Cells, Tregs, HLADR+ PD-L1+Monocytes and Myeloid-Derived Suppressor Cells: Results from a Randomized Placebo-Controlled Clinical Trial of GM-CSF in Patients with Peripheral Artery Disease